Pharmacogenetics of irinotecan disposition and toxicity: a review.

Abstract

Irinotecan (CPT-11) is a widely used anticancer drug, especially for the treatment of colorectal cancer. Irinotecan is considered an inactive prodrug that requires activation to the active metabolite SN-38. Patients treated with irinotecan occasionally experience severe neutropenia and delayed diarrhea, and the occurrence of these adverse reactions is unpredictable and still largely unexplained. Various studies have demonstrated a relationship between SN-38 pharmacokinetics and the experienced toxicity. In recent years, genetic polymorphisms in UDP-glucuronosyltransferase (UGT) 1A1, an enzyme involved in SN-38 glucuronidation, has been linked to interindividual pharmacokinetic variability and irinotecan toxicity. In addition, variants in other genes encoding drug-metabolizing enzymes or transporters that are involved in the disposition of irinotecan may play a crucial role in the pharmacokinetic and pharmacodynamic profile of irinotecan. In this review, we provide an update on the pharmacogenetics of irinotecan.

01002003002011201220132014201520162017
Citations per Year

396 Citations

Semantic Scholar estimates that this publication has 396 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Fujita2010PharmacogeneticsOI, title={Pharmacogenetics of irinotecan disposition and toxicity: a review.}, author={Ken-Ichi Fujita and Alex Sparreboom}, journal={Current clinical pharmacology}, year={2010}, volume={5 3}, pages={209-17} }